Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Fulgent Genetics Reports Second Quarter Financial Results
August 9, 2021 4:05 PM EDTRevenue grows 790% year over year to $153.6 million Core Revenue grows 296% year over year to $25.7 million Announces acquisition of CSI Laboratories Announces commercial agreement with Helio Health through strategic investment Announces incremental controlling investment in Chinese Joint Venture entity, FF Gene Biotech
TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021.
Second... More
